Edition:
India

Akero Therapeutics Inc (AKRO.OQ)

AKRO.OQ on NASDAQ Stock Exchange Global Select Market

37.00USD
18 Sep 2020
Change (% chg)

$0.84 (+2.32%)
Prev Close
$36.16
Open
$36.76
Day's High
$37.25
Day's Low
$35.95
Volume
524,809
Avg. Vol
111,038
52-wk High
$41.16
52-wk Low
$10.88

Summary

Name Age Since Current Position

Mark Iwicki

53 2019 Independent Non-Executive Chairman of the Board

Andrew Cheng

53 2018 President, Chief Executive Officer, Director

Jonathan Young

50 2018 Co-Founder, Chief Operating Officer, Executive Vice President

Timothy Rolph

66 2017 Co-Founder, Chief Scientific Officer

William White

47 2019 Chief Financial Officer, Executive Vice President and Head of Corporate Development

Kitty Yale

48 2018 Chief Development Officer

Tomas Heyman

2020 Independent Director

Kevin Bitterman

43 2018 Non-Executive Independent Director

Seth Harrison

59 2019 Non-Executive Independent Director

Jane Henderson

2019 Non-Executive Independent Director

Graham Walmsley

33 2018 Non-Executive Independent Director

Biographies

Name Description

Mark Iwicki

Mr. Mark T. Iwicki serves as Independent Non-Executive Chairman of the Board of the Company. Mr. Iwicki has served as a member of our board of directors since November 2018 and as the chairperson of our board of directors since April 2019. Mr. Iwicki currently serves as the Chairman and Chief Executive Officer of Kala Pharmaceuticals, Inc., a pharmaceutical company, where he has been employed since April 2015. From December 2012 to January 2014, Mr. Iwicki served as President and Chief Executive Officer and director at Blend Therapeutics, Inc., now known as Tarveda Therapeutics, Inc., a biotechnology company. From 2007 to June 2012, Mr. Iwicki served in several roles, including Chief Commercial Officer, President and Chief Operating Officer and Director and Chief Executive Officer at Sunovion Pharmaceuticals, Inc., formerly Sepracor, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Iwicki held executive positions, including Vice President and Business Unit Head, at Novartis Pharmaceuticals Corporation, a pharmaceutical company. Mr. Iwicki currently serves on the board of directors of Pulmatrix, Inc., a biopharmaceutical company, Aimmune Therapeutics, Inc., a biopharmaceutical company, Kala Pharmaceuticals, Inc. as well as on the board of directors of several private companies, including Nimbus Therapeutics, LLC, a biotechnology company, and Taris Biomedical, LLC, a pharmaceutical company. Mr. Iwicki received a B.A. in business administration from Ball State University and an M.B.A. from Loyola University.

Andrew Cheng

Dr. Andrew Cheng M.D., Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Cheng has served as our President and Chief Executive Officer since September 2018. Before joining the Company, Dr. Cheng was formerly at Gilead Sciences, Inc., a biotechnology company, as the Chief Medical Officer from March 2018 through September 2018, Executive Vice President from February 2015 through September 2018 and Senior Vice President from February 2009 through February 2015. During his nearly 20 year tenure, he was responsible for the clinical development for the HIV program resulting in 11 FDA/EMA approved products. His past responsibilities also included medical affairs and the creation of the development operations department (regulatory affairs, clinical operations, pharmacovigilance, project management, clinical pharmacology and biometrics) which covered clinical development support in multiple therapeutic areas including oncology, inflammation, respiratory, cardiovascular, HIV and liver diseases. Dr. Cheng has served on the board of directors of Syntimmune, Inc., a biotechnology company, which was acquired by Alexion. Dr. Cheng holds a B.A. in biology from the Johns Hopkins University and a M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine.

Jonathan Young

Dr. Jonathan Young J.D., Ph.D. serves as Co-Founder, Chief Operating Officer, Executive Vice President of the Company. Dr. Young served as our co-founder, President and Chief Executive Officer from April 2017 to September 2018, and since September 2018 as our co-founder, Executive Vice President and Chief Operating Officer. Before joining the Company, Dr. Young served as a Venture Partner at Apple Tree Partners, a venture capital firm, from October 2016 to September 2018. From August 2014 to October 2016, he served as Vice President of Policy/Advocacy and General Counsel at Braeburn Pharmaceuticals, Inc. From October 2006 through August 2014, Dr. Young served in positions of increasing responsibility at FoxKiser LLP, a legal services firm, ultimately as Partner and General Counsel. Dr. Young holds a B.A. in history from Messiah College, an M.A. and Ph.D. in American history from the University of North Carolina at Chapel Hill and a J.D. from Yale Law School.

Timothy Rolph

Dr. Timothy Rolph serves as Co-Founder, Chief Scientific Officer of the Company. Rolph served as a Venture Partner at Apple Tree Partners, a venture capital firm, from October 2016 to September 2018. From March 1994 to October 2016, Dr. Rolph served in a various roles at Pfizer Inc., a pharmaceutical company, most recently as Senior Vice President, Program Value Enhancement from July 2014 to October 2016 and as Chief Scientific Officer, Cardiovascular and Metabolic and Endocrine Disease from January 2009 to June 2014. During his tenure at Pfizer Inc., Dr. Rolph also oversaw the Company's FGF21 program. Dr. Rolph holds a B.Sc. in biochemistry from the University of London and a DPhil in muscle development from University of Oxford.

William White

Mr. William White J.D. serves as Chief Financial Officer, Executive Vice President and Head of Corporate Development of the Company. Mr. White has served as our Executive Vice President, Chief Financial Officer and Head of Corporate Development since April 2019. Before joining our company, Mr. White served as a Managing Director and Head of US Life Sciences Investment Banking at Deutsche Bank from September 2017 until March 2019. Prior to that position, Mr. White was a Managing Director in Healthcare Investment Banking at Citigroup from May 2006 until September 2017. Previously, he served as Vice President in Healthcare Investment Banking at Goldman, Sachs & Co., from April 2004 to March 2006. Mr. White received an A.B. from Princeton University, an M.P.P. from Harvard University and a J.D. from Columbia University.

Kitty Yale

Ms. Kitty Yale serves as Chief Development Officer of the Company. Before joining the Company, Ms. Yale served in various roles at Gilead Sciences, Inc., a biotechnology company, from October 2001 to October 2018, where she held senior clinical research and operations roles and led global clinical operations and management of the Company's oncology, HIV, inflammation and liver disease trials. Most recently, Ms. Yale served as Vice President of Clinical Operations at Gilead Sciences, Inc. from July 2016 to October 2018. Ms. Yale holds B.Sc. in applied biology from Glasgow Caledonian University.

Tomas Heyman

Mr. Tomas J. Heyman serves as Independent Director of the Company. Mr. Heyman most recently was the President of Johnson & Johnson Development Corporation, the corporate venture capital group of Johnson & Johnson, from April 2015 until September 2019. He also served as the Global Head of Business Development, Pharmaceuticals Group of Janssen Global Services, LLC from March 1992 to March 2015, and served as the CEO of Janssen Pharmaceutica NV in Belgium from November 2008 to November 2016. He currently serves on the board of directors of IMEC VZW in Belgium. Mr. Heyman received his Master of Law degree from Katholieke Universiteit Leuven in Belgium. He continued with post-graduate studies in International Law in Geneva, Switzerland, and post-graduate studies in Business Management at the University of Antwerp in Belgium.

Kevin Bitterman

Mr. Kevin J. Bitterman Ph.D. serves as Non-Executive Independent Director of the Company. Dr. Bitterman currently serves as a partner at venture firm Atlas Venture, or Atlas, a venture capital firm, where he has been employed since June 2017 and where he focuses on investments in life science companies. Prior to joining Atlas in June 2017, Dr. Bitterman was a partner at Polaris Partners, an investment firm, as a member of the healthcare team since July 2004. Dr. Bitterman was also the founding CEO at Editas Medicine Inc., a pharmaceutical company, Visterra Inc., a biotechnology company, and Morphic Rock, LLC, a biotechnology company. During the past five years, Dr. Bitterman has served on the board of directors of Editas Medicine, Inc., Kala Pharmaceuticals, Inc., a pharmaceutical company, Genocea Biosciences, Inc., a biosciences company, as well as on the board of directors of several private companies. Dr. Bitterman also serves as board chair of the New England Venture Capital Association. Dr. Bitterman received a B.A. in biology from Rutgers College and a Ph.D. in genetics from Harvard Medical School.

Seth Harrison

Dr. Seth L. Harrison M.D. serves as Non-Executive Independent Director of the Company. Dr. Harrison has served as the managing partner of Apple Tree Partners, a series of venture capital funds investing in early-stage life sciences companies, since 1999. During the past five years, Dr. Harrison has served as a member of the board of directors of the following biotechnology companies: HeartWare International, Inc., Novus Therapeutics, Inc., and Cerecor, Inc. Dr. Harrison also currently serves as a member of the board directors of several private companies, including Elstar Therapeutics, Inc., Limelight Bio, Inc., Stoke Therapeutics, Inc., Apple Tree Life Sciences, Inc. and Braeburn Pharmaceuticals, Inc. Dr. Harrison also serves on the board of directors of the Harrison Atelier Foundation and Tortoise Foundation. From 2002 to 2010, he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides. Dr. Harrison received an A.B. from Princeton University, an M.D. and M.B.A. both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.

Jane Henderson

Ms. Jane Pritchett Henderson serves as Non-Executive Independent Director of the Company. Ms. Henderson has served as a member of our board of directors since April 2019. Ms. Henderson currently serves as the Chief Financial Officer of Turnstone Biologics, Inc., a viral immuno-oncology company, a position she has held since June 2018. Prior to joining Turnstone Biologics, Ms. Henderson served as Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc., a gene therapy company, since January 2017. She also served as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., an oncology biopharmaceutical company, from February 2013 until November 2016, when Kolltan Pharmaceuticals was acquired by Celldex Therapeutics, Inc. Prior to Kolltan Pharmaceuticals, Ms. Henderson served in various financial and business development executive roles at biopharmaceutical companies after spending almost 20 years in health care investment banking. During the past five years, Ms. Henderson has served on the board of directors of Sesen Bio Inc., a biopharmaceutical company, and IVERIC Bio, Inc., a biopharmaceutical company. Ms. Henderson received a B.S. in psychology from Duke University.

Graham Walmsley

Mr. Graham Walmsley M.D. Ph.D. serves as Non-Executive Independent Director of the Company. Dr. Walmsley has served as a member of our board of directors since June 2018. Dr. Walmsley currently serves as a Principal at Versant Ventures, where he has been employed since July 2016 after he received his Ph.D. from Stanford University School of Medicine and where he specializes in healthcare and biotechnology investments. At Versant, Dr. Walmsley has contributed to the deployment of capital into early and mid-stage private biotechnology companies across multiple funds. In addition, Dr. Walmsley served as Head of Business Development at Jecure Therapeutics, Inc., a biotechnology company, since June 2017 through its acquisition by Roche/Genentech in November 2018. Dr. Walmsley currently serves as a board observer for Turnstone Biologics Inc., an immuno-oncology company, BlueRock Therapeutics, LP, an engineered cell therapy company and Aligos Therapeutics, Inc., a biotechnology company. He was previously a board observer for CODA Biotherapeutics, Inc., a biopharmaceutical company. Dr. Walmsley received a B.A. in molecular and cell biology from the University of California, Berkeley and an M.D. and Ph.D. from Stanford University School of Medicine.

Basic Compensation

Name Fiscal Year Total

Mark Iwicki

418,035

Andrew Cheng

5,431,810

Jonathan Young

2,133,660

Timothy Rolph

2,133,660

William White

3,525,820

Kitty Yale

320,266

Tomas Heyman

--

Kevin Bitterman

379,579

Seth Harrison

377,079

Jane Henderson

282,568

Graham Walmsley

376,579
As Of  31 Dec 2019